[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100430358":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":78,"centralContacts":82,"locations":90,"responsibleParty":598,"collaborators":46,"id":600,"slug":601,"hasResults":602,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":46,"eligibilityCriteria":606,"healthyVolunteers":602,"sex":607,"minAge":608,"maxAge":46,"enrollmentInfo":609,"targetDuration":46,"studyType":612,"phases":613,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":93,"whyStopped":46,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":630},{"fullName":5,"class":6},"Celgene","INDUSTRY",[8,19,24,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Administration of CC-220 with R-CHOP-21","EXPERIMENTAL","CC-220 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment",[13,14,15,16,17,18],"Drug: CC-220","Drug: Rituximab","Drug: Cyclophosphamide","Drug: Doxorubicin","Drug: Vincristine","Drug: Prednisone",{"label":20,"type":10,"description":21,"interventionNames":22},"Administration of CC-99282 with R-CHOP-21","CC-99282 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment",[14,15,16,17,18,23],"Drug: CC-99282",{"label":25,"type":10,"description":26,"interventionNames":27},"Administration of CC-220 with polatuzumab-R-CHP","CC-220 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment",[13,15,16,18,28,14],"Drug: Polatuzumab vedotin",{"label":30,"type":10,"description":31,"interventionNames":32},"Administration of CC-99282 with polatuzumab-R-CHP","CC-99282 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment",[15,16,18,23,28,14],[34,42,47,51,55,59,65,71,75],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","CC-220","CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.",[9,25],[40,41],"Iberdomide","BMS-986382",{"type":35,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Rituximab","Rituximab 375 mg\u002Fm2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles",[9,20],null,{"type":35,"name":48,"description":49,"armGroupLabels":50,"otherNames":46},"Cyclophosphamide","Cyclophosphamide 750mg\u002Fm2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles",[9,25,20,30],{"type":35,"name":52,"description":53,"armGroupLabels":54,"otherNames":46},"Doxorubicin","Doxorubicin 50 mg\u002Fm2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles",[9,25,20,30],{"type":35,"name":56,"description":57,"armGroupLabels":58,"otherNames":46},"Vincristine","Vincristine 1.4 mg\u002Fm2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles",[9,20],{"type":35,"name":60,"description":61,"armGroupLabels":62,"otherNames":63},"Prednisone","Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles",[9,25,20,30],[64],"Prednisolone",{"type":35,"name":66,"description":67,"armGroupLabels":68,"otherNames":69},"CC-99282","CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.",[20,30],[70],"BMS-986369",{"type":35,"name":72,"description":73,"armGroupLabels":74,"otherNames":46},"Polatuzumab vedotin","Polatuzumab vedotin 1.8 mg\u002Fkg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles",[25,30],{"type":35,"name":43,"description":76,"armGroupLabels":77,"otherNames":46},"Rituximab 375 mg\u002Fm2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles",[25,30],[79],{"name":80,"affiliation":80,"role":81},"Bristol-Myers Squibb","STUDY_DIRECTOR",[83,88],{"name":84,"role":85,"phone":86,"phoneExt":46,"email":87},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":89,"role":85,"phone":46,"phoneExt":46,"email":46},"First line of the email MUST contain NCT # and Site #.",[91,108,122,136,147,156,170,184,197,211,223,237,247,260,273,287,300,312,325,334,343,358,368,378,387,399,415,428,441,449,454,467,479,488,498,504,510,525,534,547,560,575,585],{"facility":92,"status":93,"city":94,"state":95,"zip":96,"country":97,"countryCode":98,"cosmosGeoPoint":99,"geoPoint":104,"contacts":105},"University Hospital (University Of Alabama Hospital)","RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":100,"coordinates":101},"Point",[102,103],-86.80249,33.52066,{"lat":103,"lon":102},[106],{"name":107,"role":85,"phone":46,"phoneExt":46,"email":46},"Aditi Saha, Site 162",{"facility":109,"status":93,"city":110,"state":111,"zip":112,"country":97,"countryCode":98,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Mayo Clinic - Arizona","Scottsdale","Arizona","85259",{"type":100,"coordinates":114},[115,116],-111.89903,33.50921,{"lat":116,"lon":115},[119],{"name":120,"role":85,"phone":121,"phoneExt":46,"email":46},"Javier Munoz, Site 154","000-000-0000",{"facility":123,"status":93,"city":124,"state":125,"zip":126,"country":97,"countryCode":98,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"City Of Hope National Medical Center","Duarte","California","91010",{"type":100,"coordinates":128},[129,130],-117.97729,34.13945,{"lat":130,"lon":129},[133],{"name":134,"role":85,"phone":135,"phoneExt":46,"email":46},"Geoffrey Shouse, Site 169","626-218-7478",{"facility":137,"status":138,"city":139,"state":140,"zip":141,"country":97,"countryCode":98,"cosmosGeoPoint":142,"geoPoint":146,"contacts":46},"Mayo Clinic - Jacksonville","WITHDRAWN","Jacksonville","Florida","32224",{"type":100,"coordinates":143},[144,145],-81.65565,30.33218,{"lat":145,"lon":144},{"facility":148,"status":93,"city":139,"state":140,"zip":141,"country":97,"countryCode":98,"cosmosGeoPoint":149,"geoPoint":151,"contacts":152},"Mayo Clinic Jacksonville - PPDS",{"type":100,"coordinates":150},[144,145],{"lat":145,"lon":144},[153],{"name":154,"role":85,"phone":155,"phoneExt":46,"email":46},"Muhamad Alhaj Moustafa, Site 160","904-953-2000",{"facility":157,"status":93,"city":158,"state":159,"zip":160,"country":97,"countryCode":98,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Northwest Georgia Oncology Centers PC","Marietta","Georgia","30060",{"type":100,"coordinates":162},[163,164],-84.54993,33.9526,{"lat":164,"lon":163},[167],{"name":168,"role":85,"phone":169,"phoneExt":46,"email":46},"Dean Kirkel, Site 161","770-281-5100",{"facility":171,"status":93,"city":172,"state":173,"zip":174,"country":97,"countryCode":98,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"University Of Kansas Medical Center","Kansas City","Kansas","66160",{"type":100,"coordinates":176},[177,178],-94.62746,39.11417,{"lat":178,"lon":177},[181],{"name":182,"role":85,"phone":183,"phoneExt":46,"email":46},"Marc Hoffmann, Site 159","913-574-2650",{"facility":185,"status":93,"city":186,"state":173,"zip":187,"country":97,"countryCode":98,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Cancer Center Of Kansas-Wichita","Wichita","67214",{"type":100,"coordinates":189},[190,191],-97.33754,37.69224,{"lat":191,"lon":190},[194],{"name":195,"role":85,"phone":196,"phoneExt":46,"email":46},"Shaker Dakhil, Site 166","316-262-4467",{"facility":198,"status":93,"city":199,"state":200,"zip":201,"country":97,"countryCode":98,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"Mayo Clinic - Rochester","Rochester","Minnesota","55905-0001",{"type":100,"coordinates":203},[204,205],-92.4699,44.02163,{"lat":205,"lon":204},[208],{"name":209,"role":85,"phone":210,"phoneExt":46,"email":46},"Grzegorz Nowakowski, Site 152","507-284-2511",{"facility":212,"status":93,"city":213,"state":200,"zip":214,"country":97,"countryCode":98,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"HealthPartners Cancer Research Center","Saint Louis Park","55426",{"type":100,"coordinates":216},[217,218],-93.34801,44.9483,{"lat":218,"lon":217},[221],{"name":222,"role":85,"phone":46,"phoneExt":46,"email":46},"Gordon Ruan, Site 163",{"facility":224,"status":93,"city":225,"state":226,"zip":227,"country":97,"countryCode":98,"cosmosGeoPoint":228,"geoPoint":232,"contacts":233},"University of Nebraska - Fred and Pamela Buffet Center","Omaha","Nebraska","68198",{"type":100,"coordinates":229},[230,231],-95.94043,41.25626,{"lat":231,"lon":230},[234],{"name":235,"role":85,"phone":236,"phoneExt":46,"email":46},"Matthew Lunning, Site 151","402-559-7164",{"facility":238,"status":138,"city":239,"state":240,"zip":241,"country":97,"countryCode":98,"cosmosGeoPoint":242,"geoPoint":246,"contacts":46},"Roswell Park Cancer Institute","Buffalo","New York","14263",{"type":100,"coordinates":243},[244,245],-78.87837,42.88645,{"lat":245,"lon":244},{"facility":248,"status":93,"city":249,"state":250,"zip":251,"country":97,"countryCode":98,"cosmosGeoPoint":252,"geoPoint":256,"contacts":257},"Levine Cancer Institute","Charlotte","North Carolina","28204",{"type":100,"coordinates":253},[254,255],-80.84313,35.22709,{"lat":255,"lon":254},[258],{"name":259,"role":85,"phone":46,"phoneExt":46,"email":46},"Rakhee Vaidya, Site 170",{"facility":261,"status":93,"city":262,"state":250,"zip":263,"country":97,"countryCode":98,"cosmosGeoPoint":264,"geoPoint":268,"contacts":269},"Atrium Health Wake Forest Baptist","Winston-Salem","27157",{"type":100,"coordinates":265},[266,267],-80.24422,36.09986,{"lat":267,"lon":266},[270],{"name":271,"role":85,"phone":272,"phoneExt":46,"email":46},"Rakhee Vaidya, Site 164","336-713-5440",{"facility":274,"status":93,"city":275,"state":276,"zip":277,"country":97,"countryCode":98,"cosmosGeoPoint":278,"geoPoint":282,"contacts":283},"MD Anderson Cancer Center","Houston","Texas","77003",{"type":100,"coordinates":279},[280,281],-95.36327,29.76328,{"lat":281,"lon":280},[284],{"name":285,"role":85,"phone":286,"phoneExt":46,"email":46},"Jason Westin, Site 155","713-792-3750",{"facility":288,"status":93,"city":289,"state":290,"zip":291,"country":97,"countryCode":98,"cosmosGeoPoint":292,"geoPoint":296,"contacts":297},"Intermountain Medical Oncology","Murray","Utah","84107",{"type":100,"coordinates":293},[294,295],-111.88799,40.66689,{"lat":295,"lon":294},[298],{"name":299,"role":85,"phone":46,"phoneExt":46,"email":46},"Rachel Hu, Site 168",{"facility":301,"status":93,"city":302,"state":290,"zip":303,"country":97,"countryCode":98,"cosmosGeoPoint":304,"geoPoint":308,"contacts":309},"Intermountain Cancer Center - St George","St. George","84790",{"type":100,"coordinates":305},[306,307],-113.58412,37.10415,{"lat":307,"lon":306},[310],{"name":311,"role":85,"phone":46,"phoneExt":46,"email":46},"Rachel Hu, Site 171",{"facility":313,"status":314,"city":315,"state":316,"zip":317,"country":318,"countryCode":319,"cosmosGeoPoint":320,"geoPoint":324,"contacts":46},"Local Institution - 501","COMPLETED","Adelaide","South Australia","5000","Australia","AU",{"type":100,"coordinates":321},[322,323],138.59863,-34.92866,{"lat":323,"lon":322},{"facility":326,"status":314,"city":327,"state":46,"zip":328,"country":318,"countryCode":319,"cosmosGeoPoint":329,"geoPoint":333,"contacts":46},"Local Institution - 503","Perth","WA 6000",{"type":100,"coordinates":330},[331,332],115.8614,-31.95224,{"lat":332,"lon":331},{"facility":335,"status":138,"city":336,"state":46,"zip":337,"country":318,"countryCode":319,"cosmosGeoPoint":338,"geoPoint":342,"contacts":46},"Local Institution - 502","Waratah","NSW",{"type":100,"coordinates":339},[340,341],151.72647,-32.90667,{"lat":341,"lon":340},{"facility":344,"status":93,"city":345,"state":46,"zip":346,"country":347,"countryCode":348,"cosmosGeoPoint":349,"geoPoint":353,"contacts":354},"Evangelismos General Hospital of Athens","Athens","10676","Greece","GR",{"type":100,"coordinates":350},[351,352],23.72784,37.98376,{"lat":352,"lon":351},[355],{"name":356,"role":85,"phone":357,"phoneExt":46,"email":46},"Maria Bouzani, Site 702","+302132041721",{"facility":359,"status":93,"city":345,"state":46,"zip":360,"country":347,"countryCode":348,"cosmosGeoPoint":361,"geoPoint":363,"contacts":364},"General Hospital of Athens \"Laiko\"","11 527",{"type":100,"coordinates":362},[351,352],{"lat":352,"lon":351},[365],{"name":366,"role":85,"phone":367,"phoneExt":46,"email":46},"Theodoros Vassilakopoulos, Site 704","+00302107456902",{"facility":369,"status":93,"city":345,"state":46,"zip":370,"country":347,"countryCode":348,"cosmosGeoPoint":371,"geoPoint":373,"contacts":374},"Attikon University General Hospital","12464",{"type":100,"coordinates":372},[351,352],{"lat":352,"lon":351},[375],{"name":376,"role":85,"phone":377,"phoneExt":46,"email":46},"Vasiliki Pappa, Site 701","00306937255084",{"facility":379,"status":138,"city":380,"state":46,"zip":381,"country":347,"countryCode":348,"cosmosGeoPoint":382,"geoPoint":386,"contacts":46},"Local Institution - 703","Pátrai","26500",{"type":100,"coordinates":383},[384,385],21.73508,38.2462,{"lat":385,"lon":384},{"facility":388,"status":93,"city":389,"state":46,"zip":390,"country":347,"countryCode":348,"cosmosGeoPoint":391,"geoPoint":395,"contacts":396},"Georgios Papanikolaou General Hospital of Thessaloniki","Thessaloniki","57010",{"type":100,"coordinates":392},[393,394],22.93493,40.64072,{"lat":394,"lon":393},[397],{"name":398,"role":85,"phone":46,"phoneExt":46,"email":46},"Ioanna Sakellari, Site 700",{"facility":400,"status":93,"city":401,"state":402,"zip":403,"country":404,"countryCode":405,"cosmosGeoPoint":406,"geoPoint":410,"contacts":411},"AIDPORT Sp. z o.o.","Skórzewo","Greater Poland Voivodeship","60-185","Poland","PL",{"type":100,"coordinates":407},[408,409],16.78934,52.39085,{"lat":409,"lon":408},[412],{"name":413,"role":85,"phone":414,"phoneExt":46,"email":46},"Michal Kwiatek, Site 605","48793602210",{"facility":416,"status":93,"city":417,"state":46,"zip":418,"country":404,"countryCode":405,"cosmosGeoPoint":419,"geoPoint":423,"contacts":424},"Uniwersyteckie Centrum Kliniczne","Gdansk","80-952",{"type":100,"coordinates":420},[421,422],18.64912,54.35227,{"lat":422,"lon":421},[425],{"name":426,"role":85,"phone":427,"phoneExt":46,"email":46},"Michal Taszner, Site 601","600063660",{"facility":429,"status":93,"city":430,"state":46,"zip":431,"country":404,"countryCode":405,"cosmosGeoPoint":432,"geoPoint":436,"contacts":437},"MCM Krakow - PRATIA - PPDS","Krakow","30-727",{"type":100,"coordinates":433},[434,435],19.93658,50.06143,{"lat":435,"lon":434},[438],{"name":439,"role":85,"phone":440,"phoneExt":46,"email":46},"Wojciech Jurczak, Site 600","+48602338290",{"facility":442,"status":138,"city":443,"state":46,"zip":403,"country":404,"countryCode":405,"cosmosGeoPoint":444,"geoPoint":448,"contacts":46},"Local Institution - 0706","Poznan",{"type":100,"coordinates":445},[446,447],16.92993,52.40692,{"lat":447,"lon":446},{"facility":450,"status":138,"city":443,"state":46,"zip":403,"country":404,"countryCode":405,"cosmosGeoPoint":451,"geoPoint":453,"contacts":46},"Local Institution - UNK0706",{"type":100,"coordinates":452},[446,447],{"lat":447,"lon":446},{"facility":455,"status":93,"city":456,"state":46,"zip":457,"country":404,"countryCode":405,"cosmosGeoPoint":458,"geoPoint":462,"contacts":463},"SP ZOZ Szpital Uniwersytecki w Krakowie","Słomniki","32-090",{"type":100,"coordinates":459},[460,461],20.08224,50.24012,{"lat":461,"lon":460},[464],{"name":465,"role":85,"phone":466,"phoneExt":46,"email":46},"Dagmara Zimowska-Curylo, Site 603","+48122954139",{"facility":468,"status":93,"city":469,"state":46,"zip":470,"country":404,"countryCode":405,"cosmosGeoPoint":471,"geoPoint":475,"contacts":476},"Local Institution - 602","Warsaw","02-781",{"type":100,"coordinates":472},[473,474],21.01178,52.22977,{"lat":474,"lon":473},[477],{"name":478,"role":85,"phone":46,"phoneExt":46,"email":46},"Site 602",{"facility":480,"status":314,"city":481,"state":46,"zip":482,"country":404,"countryCode":405,"cosmosGeoPoint":483,"geoPoint":487,"contacts":46},"Local Institution - 604","Wroclaw","50-367",{"type":100,"coordinates":484},[485,486],17.03006,51.10286,{"lat":486,"lon":485},{"facility":489,"status":314,"city":490,"state":46,"zip":491,"country":492,"countryCode":46,"cosmosGeoPoint":493,"geoPoint":497,"contacts":46},"Local Institution - 300","Seoul","06351","South Korea",{"type":100,"coordinates":494},[495,496],126.9784,37.566,{"lat":496,"lon":495},{"facility":499,"status":314,"city":490,"state":46,"zip":500,"country":492,"countryCode":46,"cosmosGeoPoint":501,"geoPoint":503,"contacts":46},"Local Institution - 302","138-736",{"type":100,"coordinates":502},[495,496],{"lat":496,"lon":495},{"facility":505,"status":314,"city":490,"state":46,"zip":506,"country":492,"countryCode":46,"cosmosGeoPoint":507,"geoPoint":509,"contacts":46},"Local Institution - 301","3080",{"type":100,"coordinates":508},[495,496],{"lat":496,"lon":495},{"facility":511,"status":93,"city":512,"state":46,"zip":513,"country":514,"countryCode":515,"cosmosGeoPoint":516,"geoPoint":520,"contacts":521},"Hospital Universitari Germans Trias i Pujol ICO Badalona","Barcelona","08916","Spain","ES",{"type":100,"coordinates":517},[518,519],2.15899,41.38879,{"lat":519,"lon":518},[522],{"name":523,"role":85,"phone":524,"phoneExt":46,"email":46},"Juan Manuel Sancho, Site 201","+34934978987",{"facility":526,"status":138,"city":527,"state":46,"zip":528,"country":514,"countryCode":515,"cosmosGeoPoint":529,"geoPoint":533,"contacts":46},"Local Institution - 204","Madrid","28028",{"type":100,"coordinates":530},[531,532],-3.70256,40.4165,{"lat":532,"lon":531},{"facility":535,"status":93,"city":536,"state":46,"zip":537,"country":514,"countryCode":515,"cosmosGeoPoint":538,"geoPoint":542,"contacts":543},"H. Virgen de la Victoria","Málaga","29010",{"type":100,"coordinates":539},[540,541],-4.42034,36.72016,{"lat":541,"lon":540},[544],{"name":545,"role":85,"phone":546,"phoneExt":46,"email":46},"Antonio Rueda-Domínguez, Site 203","+34951032467 00 000",{"facility":548,"status":93,"city":549,"state":46,"zip":550,"country":514,"countryCode":515,"cosmosGeoPoint":551,"geoPoint":555,"contacts":556},"Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca","Salamanca","37007",{"type":100,"coordinates":552},[553,554],-5.66388,40.96882,{"lat":554,"lon":553},[557],{"name":558,"role":85,"phone":559,"phoneExt":46,"email":46},"Alejandro Martin Garcia-Sancho, Site 200","+34980548200",{"facility":561,"status":93,"city":562,"state":46,"zip":563,"country":564,"countryCode":565,"cosmosGeoPoint":566,"geoPoint":570,"contacts":571},"China Medical University Hospital","Taichung","40447","Taiwan","TW",{"type":100,"coordinates":567},[568,569],120.6839,24.1469,{"lat":569,"lon":568},[572],{"name":573,"role":85,"phone":574,"phoneExt":46,"email":46},"Tai-Chung Huang, Site 403","886972651392",{"facility":576,"status":93,"city":562,"state":46,"zip":577,"country":564,"countryCode":565,"cosmosGeoPoint":578,"geoPoint":580,"contacts":581},"Taichung Veterans General Hospital","407",{"type":100,"coordinates":579},[568,569],{"lat":569,"lon":568},[582],{"name":583,"role":85,"phone":584,"phoneExt":46,"email":46},"Chieh-Lin Teng, Site 402","0423592525EXT3176",{"facility":586,"status":93,"city":587,"state":46,"zip":588,"country":564,"countryCode":565,"cosmosGeoPoint":589,"geoPoint":593,"contacts":594},"National Taiwan University Hospital","Taipei","100229",{"type":100,"coordinates":590},[591,592],121.52639,25.05306,{"lat":592,"lon":591},[595],{"name":596,"role":85,"phone":597,"phoneExt":46,"email":46},"Tai-Chung Huang, Site 400","+886972651392",{"type":599,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR","100430358","phase-1-study-of-safety-and-efficacy-of-iberdomide-cc-220-and-cc-99282-combined-with-r-chop-to-treat-lymphoma-100430358",false,"NCT04884035","Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma","Inclusion Criteria:\n\n* Participants must satisfy the following criteria to be enrolled in the study:\n\n  1. Is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n  2. Participant has histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated, a-BCL according to 2016 WHO classification.\n  3. Participant has International Prognostic Index (IPI) score 0-5 in Part 1 and IPI 2-5 in Part 2. For the CELMoD and polatuzumab-R-CHP cohort, the subject must also have IPI score 0 to 5 in Part 2A and IPI 2 to 5 in Part 2B.\n  4. Participants must have measurable disease defined by at least one FDG-avid lesion for FDG-avid subtype and one bi-dimensionally measurable (\\> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification (Cheson, 2014).\n  5. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n  6. Participants must have the following laboratory values:\n\n     1. Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL or ≥ 1.0 x 109\u002FL in case of documented bone marrow involvement (\\> 50% or tumor cells), without growth factor support for 7 days (14 days if peg-G-CSF)\n     2. Hemoglobin (Hb) ≥ 8 g\u002FdL\n     3. Platelets (PLT) ≥ 75 x 109\u002FL or ≥ 50 x 109\u002FL in case of documented bone marrow involvement (\\>50% or tumor cells), without transfusion for 7 days\n     4. Aspartate aminotransferase \u002F serum glutamic oxaloacetic transaminase (AST\u002FSGOT) and alanine aminotransferase \u002F serum glutamate pyruvic transaminase (ALT\u002FSGPT) ≤ 2.5 x upper limit of normal (ULN). In the case of documented liver involvement by lymphoma, ALT\u002FSGPT and AST\u002FSGOT must be ≤ 5.0 x ULN.\n     5. Serum total bilirubin ≤ 2.0 mg\u002FdL except in cases of Gilbert's syndrome, then ≤ 5.0 mg\u002Fdl. Subjects receiving polatuzumab vedotin must have serum total bilirubin \\\u003C 1.5 × ULN (26 μmol\u002FL) (corresponding to mild degree as per National Cancer Institute Organ Dysfunction Working Group \\[NCI ODWG\\] criteria) except in cases of Gilbert's syndrome, then ≤ 3.0 mg\u002Fdl (51 μmol\u002FL).\n     6. Estimated serum creatinine clearance (CrCl) of ≥ 50 mL\u002Fmin using the modification of diet in renal disease (MDRD) formula.\n  7. All participants must:\n\n     1. Have an understanding that the study drug could have a potential teratogenic risk.\n     2. Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 or CC-99282 Pregnancy Prevention Plan for Participants in Clinical trials.\n  8. Females of childbearing potential (FCBP) must:\n\n     a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy.\n  9. Male participants must:\n\n     1. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.\n\nExclusion Criteria:\n\n* The presence of any of the following will exclude a participant from enrollment:\n\n  1. Any significant medical condition, active infection (including SARS-CoV-2 suspected or confirmed), laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.\n  2. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he\u002Fshe were to participate in the study.\n  3. Any other subtype of lymphoma.\n  4. Documented or suspected CNS involvement by lymphoma.\n  5. Persistent diarrhea or malabsorption ≥ Grade 2 (NCI CTCAE v5.0), despite medical management.\n  6. Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v5.0).\n  7. Subjects with a history of progressive multifocal leukoencephalopathy.\n  8. Chronic systemic immunosuppressive therapy or corticosteroids\n  9. Impaired cardiac function or clinically significant cardiac disease, including any of the following:\n\n     a. Left ventricular ejection fraction (LVEF) \\\u003C 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)\n  10. Major surgery ≤ 2 weeks prior to starting CC-220 or CC-99282; participant must have recovered from any clinically significant effects of recent surgery.\n  11. Any condition causing inability to swallow tablets.\n  12. Known seropositivity for or active viral infection with human immunodeficiency virus (HIV)\n  13. Known chronic active hepatitis B (hepatitis B virus surface antigen \\[HBsAg\\] positive and\u002For hepatitis B core antibody \\[anti-HBc\\] positive with viral DNA positive) or C (positive serology requiring treatment and\u002For with evidence of liver damage) infection\n  14. History of other malignancy, unless being free of the disease for ≥ 3 years; exceptions to the ≥ 3-year time limit include history of the following:\n\n      1. Localized nonmelanoma skin cancer\n      2. Carcinoma in situ of the cervix\n      3. Carcinoma in situ of the breast\n      4. Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis \\[TNM\\] staging system) or prostate cancer that has been treated with curative intent.\n  15. Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients of rituximab or polatuzumab vedotin.\n  16. Known hypersensitivity to any component of CHOP\u002FCHP regimen.\n  17. Known allergy to thalidomide, pomalidomide, or lenalidomide.","ALL","18 Years",{"count":610,"type":611},224,"ESTIMATED","INTERVENTIONAL",[614],"PHASE1","This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and\u002For CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and\u002For CC-99282 and R-CHOP-21 combination has been defined.",[617],"Lymphoma, B-Cell",[40,36,66,619,620],"Phase 1","B-Cell Lymphoma","2026-06-05",{"date":623,"type":624},"2026-06-08","ACTUAL",{"date":626,"type":624},"2021-09-15",{"date":628,"type":611},"2028-12-01",{"name":5,"class":6},43]